Original Research

Veterans’ Use of Designer Cathinones and Cannabinoids

Fed Pract. 2014 November;31(11):22-27

References

1. Bray RM, Fairbank JA, Marsden ME. Stress and substance use among military women and men. J Drug Alcohol Abuse. 1999;25(2):239-256.

2. Bray RM, Hourani LL. Substance use trends among active duty military personnel: Findings from the United States Department of Defense Health Related Behavior Surveys, 1980-2005. Addiction. 2007;102(7):1092-1101.

3. Hankin CS, Spiro A 3rd, Miller DR, Kazis L. Mental disorders and mental health treatment among U.S. Department of Veterans Affairs outpatients: The Veterans Health Study. Am J Psychiatry. 1999;156(12):1924-1930.

4. Sirratt D, Ozanian A, Traenkner B. Epidemiology and prevention of substance use disorders in the military. Mil Med. 2012;177(suppl 8):21-28.

5. Winder GS, Stern N, Hosanagar A. Are “bath salts” the next generation of stimulant abuse? J Subst Abuse Treat. 2013;44(1):42-45.

6. Bobes J, Sáiz PA, González MP, et al. Use of MDMA and other illicit drugs by young adult males in northern Spain. A five-year study. Eur Addict Res. 2002;8(3):147-154.

7. D.E.A. Cracks Down on Designer Drug Operations. The New York Times Website. http://www.nytimes.com/2013/06/27/us/dea-cracks-down-on-designer-drug-operations.html. Published June 26, 2013. Accessed October 6, 2014.

8. Travis A. Mushrooming legal highs leave drug control system floundering, UN warns. The Guardian Website. http://www.guardian.co.uk/world/2013/jun/26/legal-highs-drug-control. Published June 26, 2013. Accessed October 6, 2014.

9. Jerry J, Collins G, Streem D. Synthetic legal intoxicating drugs: The emerging ‘incense’ and ‘bath salt’ phenomenon. Cleve Clin J Med. 2012;79(4):258-264.

10. Murphy CM, Dulaney AR, Beuhler MC, Kacinko S. “Bath salts” and “plant food” products: The experience of one regional US poison center. J Med Toxicol. 2013;9(1):42-48.

11. Wax PM. Just a click away: Recreational drug web sites on the Internet. Pediatrics. 2002;109(6):e96.

12. Vardakou I, Pistos C, Spiliopoulou C. Drugs for youth via Internet and the example of mephedrone. Toxicol Lett. 2011;201(3):191-195.

13. Winickoff JP, Houck CS, Rothman EL, Bauchner H. Verve and jolt: Deadly new Internet drugs. Pediatrics. 2000;106(4):829-830.

14. Camilleri A, Johnston MR, Brennan M, Davis S, Caldicott DG. Chemical analysis of four capsules containing the controlled substance analogues 4-methylmethcathinone, 2-fluoromethamphetamine, alpha-phthalimidopropiophenone and N-ethylcathinone. Forensic Sci Int. 2010;197(1-3):59-66.

15. Carroll FI, Lewin AH, Mascarella SW, Seltzman HH, Reddy PA. Designer drugs: A medicinal chemistry perspective. Ann N Y Acad Sci. 2012;1248:18-38.

16. Christophersen AS. Amphetamine designer drugs—An overview and epidemiology. Toxicol Lett. 2000;112-113:127-131.

17. Buchanan JF, Brown CR. ‘Designer drugs.’ A problem in clinical toxicology. Med Toxicol Adverse Drug Exp. 1988;3(1):1-17.

18. Griffiths P, Sedefov R, Gallegos A, Lopez D. How globalization and market innovation challenge how we think about and respond to drug use: ‘Spice’ a case study. Addiction. 2010;105(6):951-953.

19. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: Temporary placement of three synthetic cathinones in Schedule I. Final Order. Fed Regist. 2011;76(204):65371-65375.

20. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: Placement of five synthetic cannabinoids into Schedule I. Fed Regist. 2012;77(41):12508-12514.

21. Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: Temporary placement of three synthetic cannabinoids into Schedule I. Fed Regist. 2013;78(95):28735-28739.

22. Council of the European Union. Council Decision of 2 December 2010 on submitting 4-methylmethcathinone (mephedrone) to control measures. EUR-Lex Website. eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2010:322:0044:0045:en:PDF. Published December 8, 2010. Accessed October 7, 2014.

23. European Monitoring Centre for Drugs and Drug Addiction. Synthetic cannabinoids and ‘spice’. European Monitoring Centre for Drugs and Drug Addiction Website. http://www.emcdda.europa.eu/publications/drug-profiles/synthetic-cannabinoids. Updated September 15, 2011. Accessed October 7, 2014.

24. United Nations Office on Drugs and Crime. World Drug Report 2014. United Nations Office on Drugs and Crime Website. http://www.unodc.org/wdr2014. Accessed October 3, 2014.

25. Fass JA, Fass AD, Garcia AS. Synthetic cathinones (bath salts): Legal status and patterns of abuse. Ann Pharmacother. 2012;46(3):436-441.

26. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. “Spice” and “K2” herbal highs: A case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21(4):320-326.

27. Loeffler G, Hurst D, Penn A, Yung K. Spice, bath salts, and the U.S. military: The emergence of synthetic cannabinoid receptor agonists and cathinones in the U.S. Armed Forces. Mil Med. 2012;177(9):1041-1048.

28. European Monitoring Centre for Drugs and Drug Addiction. Understanding the spice phenomenon. The National Documentation Centre on Drug Use Website. http://www.drugsandalcohol.ie/12597/1/Understanding_the_Spice_phenomenon.pdf. Published 2009. Accessed October 7, 2014.

29. Davies S, Wood DM, Smith G, et al. Purchasing ‘legal highs’ on the Internet—Is there consistency in what you get? QJM. 2010;103(7):489-493.

30. Harris CR, Brown A. Synthetic cannabinoid intoxication: A case series and review. J Emerg Med. 2013;44(2):360-366.

31. Ammann D, McLaren JM, Gerostamoulos D, Beyer J. Detection and quantification of new designer drugs in human blood: Part 2--Designer cathinones. J Anal Toxicol. 2012;36(6):381-389.

32. Hudson S, Ramsey J. The emergence and analysis of synthetic cannabinoids. Drug Test Anal. 2011;3(7-8):466-478.

33. Al-Habori M. The potential adverse effects of habitual use of Catha edulis (khat). Expert Opin Drug Saf. 2005;4(6):1145-1154.

34. Al-Motarreb A, Al-Habori M, Broadley KJ. Khat chewing, cardiovascular diseases and other internal medical problems: The current situation and directions for future research. J Ethnopharmacol. 2010;132(3):540-548.

35. Dargan PI, Sedefov R, Gallegos A, Wood DM. The pharmacology and toxicology of the synthetic cathinone mephedrone (4-methylmethcathinone). Drug Test Anal. 2011;3(7-8):454-463.

36. Kriikku P, Wilhelm L, Schwarz O, Rintatalo J. New designer drug of abuse:  3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. Forensic Sci Int. 2011;210(1-3):195-200.

37. Morris K. UK places generic ban on mephedrone drug family. Lancet. 2010;375(9723):1333-1334.

38. Garrett G, Sweeney M. The serotonin syndrome as a result of mephedrone toxicity. BMJ Case Rep. 2010.

39. Sammler EM, Foley PL, Lauder GD, Wilson SJ, Goudie AR, O’Riordan JI. A harmless high? Lancet. 2010;376(9742):742.

40. Prosser JM, Nelson LS. The toxicology of bath salts: A review of synthetic cathinones. J Med Toxicol. 2012;8(1):33-42.

41. Thornton SL, Gerona RR, Tomaszewski CA. Psychosis from a bath salt product containing flephedrone and MDPV with serum, urine, and product quantification. J Med Toxicol. 2012;8(3):310-313.

42. Emerson TS, Cisek JE. Methcathinone: a Russian designer amphetamine infiltrates the rural midwest. Ann Emerg Med. 1993;22(12):1897-1903.

43. Winstock AR, Mitcheson LR, Deluca P, Davey Z, Corazza O, Schifano F. Mephedrone, new kid for the chop? Addict. 2011;106(1):154-161.

44. Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States. Clin Toxicol (Phila). 2011;49(6):499-505.

45. Ojanperä IA, Heikman PK, Rasanen IJ. Urine analysis of 3,4-methylenedioxypyrovalerone in opioid-dependent patients by gas chromatography-mass spectrometry. Ther Drug Monit. 2011;33(2):257-263.

46. Meyer MR, Du P, Schuster F, Maurer HH. Studies on the metabolism of the alpha-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. JMS. 2010;45(12):1426-1442.

47. Santali EY, Cadogan AK, Daeid NN, Savage KA, Sutcliffe OB. Synthesis, full chemical characterisation and development of validated methods for the quantification of (+/-)-4’-methylmethcathinone (mephedrone): A new “legal high”. J Pharm Biomed Anal. 2011;56(2):246-255.

48. Meyer MR, Vollmar C, Schwaninger AE, Wolf E, Maurer HH. New cathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: Studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine. JMS. 2012;47(2):253-262.

49. Borek HA, Holstege CP. Hyperthermia and multiorgan failure after abuse of “bath salts” containing 3,4-methylenedioxypyrovalerone. Ann Emerg Med. 2012;60(1):103-105.

50. Kasick DP, McKnight CA, Klisovic E. “Bath salt” ingestion leading to severe intoxication delirium: Two cases and a brief review of the emergence of mephedrone use. Am J Drug Alcohol Abuse. 2012;38(2):176-180.

51. Penders TM, Gestring RE, Vilensky DA. Excited delirium following use of synthetic cathinones (bath salts). Gen Hosp Psychiatry. 2012;34(6):647-650.

52. Nicholson PJ, Quinn MJ, Dodd JD. Headshop heartache: Acute mephedrone ‘meow’ myocarditis. Heart. 2010;96(24):2051-2052.

53. Murray BL, Murphy CM, Beuhler MC. Death following recreational use of designer drug “bath salts” containing 3,4-Methylenedioxypyrovalerone (MDPV). J Med Toxicol. 2012;8(1):69-75.

54. Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL. Spice” and “K2” herbal highs: A case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21(4):320-326.

55. Schneir AB, Cullen J, Ly BT. “Spice” girls: Synthetic cannabinoid intoxication. J Emerg Med. 2011;40(3):296-299.

56. Atwood BK, Huffman J, Straiker A, Mackie K. JWH018, a common constituent of ‘Spice’ herbal blends, is a potent and efficacious cannabinoid CB receptor agonist. Br J Pharmacol. 2010;160(3):585-593.

57. Uchiyama N, Kikura-Hanajiri R, Ogata J, Goda Y. Chemical analysis of synthetic cannabinoids as designer drugs in herbal products. Forensic Sci Int. 2010;198(1-3):31-38.

58. Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug Alcohol Depend. 2011;117(2-3):152-157.

59. Zimmermann US, Winkelmann PR, Pilhatsch M, Nees JA, Spanagel R, Schulz K. Withdrawal phenomena and dependence syndrome after the consumption of “spice gold.” Deutsches Ärzteblatt Int. 2009;106(27):464-467.

60. Loeffler G, Hurst D, Penn A, Yung K. Spice, Bath salts, and the US military: The emergence of synthetic cannabinoid receptor agonists and cathinones in the US armed forces. Mil Med. 2012;177(9):1041-1048.

61. Devane WA, Breuer A, Sheskin T, Jäerbe TU, Eisen MS, Mechoulam R. A novel probe for the cannabinoid receptor. J Med Chem. 1992;35(11):2065-2069.

62. Gottardo R, Chiarini A, Dal Prà I, et al. Direct screening of herbal blends for new synthetic cannabinoids by MALDI-TOF MS. JMS. 2012;47(1):141-146.

63. McGrath J, Welham J, Scott J, et al. Association between cannabis use and psychosis-related outcomes using sibling pair analysis in a cohort of young adults. Arch Gen Psychiatry. 2010;67(5):440-447.

64. Every-Palmer S. Warning: Legal synthetic cannabinoid-receptor agonists such as JWH-018 may precipitate psychosis in vulnerable individuals. Addict. 2010;105(10):1859-1860.

65. Hurst D, Loeffler G, McLay R. Psychosis associated with synthetic cannabinoid agonists: A case series. Am J Psychiatry. 2011;168(10):1119.

66. Peglow S, Buchner J, Briscoe G. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict. 2012;21(3):287-288.

67. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008;192(4):306-307.

68. ElSohly MA, Gul W, ElSohly KM, Murphy TP, Madgula VL, Khan SI. Liquid chromatography-tandem mass spectrometry analysis of urine specimens for K2 (JWH-018) metabolites. J Anal Toxicol. 2011;35(7):487-495.

69. Grigoryev A, Savchuk S, Melnik A, et al. Chromatography–mass spectrometry studies on the metabolism of synthetic cannabinoids JWH-018 and JWH-073, psychoactive components of smoking mixtures. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(15-16):1126-1136.

70. Sobolevsky T, Prasolov I, Rodchenkov G. Detection of JWH-018 metabolites in smoking mixture post-administration urine. Forensic Sci Int. 2010;200(1):141-147.

Many synthetic cannabinoid herbal mixes also contain a detectable compound called tocopherol, seemingly added as an antioxidant.^69,70 Synthetic cannabinoids are an evolving drug class, and reliable detection will require that laboratories stay up-to-date in their detection methods. As stated earlier, a commercial laboratory in the region accepted the civilian and veteran patient samples for these case studies. The synthetic cannabinoid panels offered evaluation of the drug itself (GC-MS), an oral fluid screen (LC-MS), and isolation of metabolites in urine (enzyme-linked immunosorbent assay).

Conclusion

Designer drugs will remain a challenge for providers caring for veterans for several key reasons: (1) Veterans are a vulnerable population who abuse substances at higher rates than do their civilian counterparts; (2) Chemists are able to manufacture variations of known habit-forming substances; (3) Modern technology facilitates the purchase and wide distribution of addictive substances; (4) Many designer drugs are deceptively packaged and marketed; (5) The effects of the drugs are often severe; (6) No standardized treatment guidelines exist; and (7) Detection of the drugs is difficult, and new versions of the molecules may evade even cutting-edge techniques.

Due to the high cost of detecting synthetic cathinones and synthetic cannabinoids in body fluids, screening should be considered only in settings where severe symptoms are accompanied by reasonable clinical suspicion of use and an otherwise negative toxicologic workup. As more designer drugs inevitably emerge, research will be needed on their pharmacology, toxidromes, and detection. Military and civilian practitioners must remain abreast of the dynamic trends in designer drugs to ensure that their patients receive the highest level of medical care.

Author disclosures
The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the U.S. Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.